Researchers investigated the ability of a recombinant BTN2A2-IgG2a Fc fusion protein to treat Collagen type II (CIA). They showed that administration of BTN2A2-Ig attenuatex established CIA, as compared with control Ig protein treatment.
[Scientific Reports]